Predicting outcomes of primary and metastatic pancreatic cancer with principles of mass transport

Eugene J. Koay, M.D., Ph.D.
Assistant Professor
Department of Radiation Oncology
MD Anderson Cancer Center

July 12, 2015

Connecting biology and physics of cancer





THEORY OF CELL KILL FROM THERAPY


Mass transport in liver metastasis and GBM			
Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements Jennifer Pascal**, Elaine L. Beare***, Zihihui Wang**, Eugene J. Koay*, Steven A. Curley*, and Vittorio Cristini***			
PNAS, 2013	Central visid Lobute		
	$\begin{split} f_{\rm BB} &= f_{\rm BB}^{\rm ab}(m_0) \cdot {\rm BVF} \cdot \frac{JL_0 \cdot K_1(n_0/L) - 2L_1 \cdot K_1(n_c/L) \cdot (r_0^2 - r_0^2) \cdot K_0(n_c/L)}{r_0^2 \cdot (K_0(n_c/L) - K_0(n_c/L))}, \text{[1a]} \\ &= \frac{\kappa_0(n_c/L)}{K_0(n_c/L)} \cdot \frac{K_0(n_c/L)}{K_0(n_c/L)} \end{split}$		

Mathematical prediction of response and correspondence with enhancement Application of response and correspondence with enhancement Application of the second of the sec


MEASURING AND MODELING DRUG DISTRIBUTION









Mass transport correlations: Delivery Response Response to therapy (proportion of viable cancer cells)





APPLICATION TO PANCREATIC	
CANCER LIVER METASTASES	

Mass transport of liver metastases





Based on characteristics of metastasis and surrounding liver: Type I Type II


Differential responses based on transport characteristic

153 liver metastases:

- Partial response (PR)Type I: 23 of 98Type II: 17 of 55
- Progressive disease (PD)
 Type I: 26 of 98
 Type II: 3 of 55
- Stable disease (SD)Type I: 35 of 98Type II: 22 of 55
- Complete remission (CR)Type I: 3 of 98Type II: 1 of 55











Fast growth rate of cancer cells relative to relaxation (λ_M = 1.5) T = 15 0.8 0.6 0.4 Vittorio Cristini John Lowengrub


Slow growth rate of cancer cells relative to relaxation ($\lambda_M = 0.5$) T = 22 0.8 0.6 0.4 0.2 Vittorio Cristini John Lowengrub












Translating mathematical and physical oncology to patients with pancreatic cancer

- Math models inform clinical studies, vice versa
- Mass transport properties reflect the underlying biology of disease
- Approach enables stratification and possibly selection for therapy
- Prospective trials open and accruing



Acknowledgments

- NIH: Center for Transport Oncophysics
- Lustgarten Foundation
- Anne Eastland Spears Fellowship PANCAN-AACR Award
- RSNA Seed Grant
- Khalifa Foundation
- Center for Radiation Oncology Research
- HMRI:
 - Mauro Ferrari, Ph.D.
 - Haifa Shen, M.D., Ph.D.
 - Dickson Kirui, Ph.D. Karen Mann, Ph.D.
- UNM:
- Vittorio Cristini, Ph.D.
- Bill Wang, Ph.D.
- John Lowengrub, Ph.D.

- MDACC
 - Jason Fleming, M.D.
 - Mark Truty, M.D.
 - Deyali Chatterjee, M.D.
 - Matthew Katz, M.D.
 - Huamin Wang, M.D.
 - Gauri Varadhachary, M.D.
 - Bill Plunkett, Ph.D.
 - Eric Tamm, M.D. Priya Bhosale, M.D.
 - Bob Wolff, M.D.
 - Jeffrey Lee, M.D.
 - Vijaya Gottumakala, M.D.
 - Jim Abbruzzese, M.D.
 - Mark Rozner, M.D.
 - Chris Crane, M.D.
 - Anirban Maitra, M.D.

Acknowledgments	
Contact information: ekoay@mdanderson.org	